Esco Aster, a leading independent contract development and manufacturing organization dedicated to Singapore’s R&D ecosystem, has signed a Memorandum of Understanding (MOU) with A*STAR’s Bioprocessing Technology Institute (BTI) to accelerate advanced manufacturing of biological products through efficient and highly scalable bioprocessing platforms.
The signing of the MOU is Esco Aster’s first with BTI – a national research institute with core expertise in bioprocessing technology and engineering.
As part of the MOU, Esco Aster aims to establish an “Innovation Centre for Continuous Biomanufacturing”, and contribute resources to collaborative projects with Singapore-based researchers.
“Esco Aster is extremely excited about the MOU”, said Xiangliang Lin, Esco Aster’s Chief Executive Officer, “We hope to contribute to Future Economy and Industry 4.0. Our partners can consider continuous bioprocessing platform, as a paradigm shift in biologics manufacturing at the start of a R&D project; this will be a significant benefit not only to patients, clinicians, but nurturing other Singapore startups.”
Esco Aster Pte Ltd
21 Changi South Street 1
T: +65 6542 0833
E: [email protected]
Esco Aster CDMO Laboratory
Blk 71 Ayer Rajah Crescent #07-26
About Tide Motion Bioreactors
Tide motion pertains to the oscillation of culture medium into and out of the matrix vessel that intermittently exposes the cells to aeration and nutrition. The upward oscillation exposes the cells to nutrition, while the downward oscillation exposes the cells to aeration and at the same time washes away products and wastes. This gentle oscillation produces no air bubbles and causes very minimal shear stress, which are both detrimental to the cells. View a range of products at http://www.escoaster.com/tide-technology.
About Esco Aster
Esco Aster is a contract development and manufacturing organisation (CDMO) focusing on offering vaccine-, cell- and gene-therapy development and biomanufacturing services using its proprietary TideMotion™ technology, bioprocessing and bioengineering equipment.
Esco Aster aims to be a best-in-class cGMP CDMO, enabling the production of larger quantities of biologics materials needed for preclinical toxicology studies, clinical trials and eventual commercialisation, thus accelerating the transition of novel technologies from laboratory to patients in need. For more information on Esco Aster, please visit www.escoaster.com.